Medgenics Announces Filing of Shelf Registration
October 16 2012 - 5:18PM
Business Wire
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU,
MEDG) (the “Company”) today announced that it has filed a shelf
registration statement on Form S-3 with the Securities and Exchange
Commission (“SEC”).
Under the shelf registration statement, once declared effective
by the SEC, the Company may offer and sell from time to time in the
future, in one or more offerings, common stock, warrants, rights or
units consisting of any combination of the foregoing. The aggregate
offering price of all securities that may be sold under the
registration statement will not exceed $150,000,000.
The shelf registration statement is intended to give Medgenics
additional flexibility to finance business opportunities in the
future by accessing the capital markets on a timely and cost
effective basis. The specifics of any future offering, along with
the prices and terms of any such securities offered by the Company,
will be determined at the time of any such offering and will be
described in detail in a prospectus supplement filed in connection
with such offering.
The shelf registration statement relating to these securities
has been filed with the SEC but has not yet become effective. These
securities may not be sold nor may offers to buy be accepted prior
to the time the shelf registration statement becomes effective.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy the securities, nor shall there be
any sale of the securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or jurisdiction. Any offering of the securities covered by
the shelf registration statement will only be by means of a
prospectus and an accompanying prospectus supplement.
About Medgenics
Medgenics is developing Biopump™, a proprietary tissue-based
platform technology for the sustained production and delivery of
therapeutic proteins using the patient's own skin biopsy for the
treatment of a range of chronic diseases including anemia,
hepatitis, and hemophilia, among others.
Forward-looking Statements
This release contains “forward-looking statements” as that term
is defined in the Private Securities Litigation Reform Act of 1995,
which include all statements other than statements of historical
fact. Forward-looking statements are sometimes identified by their
use of the terms and phrases such as "estimate," "project,"
"intend," "forecast," "anticipate," "plan," "planning, "expect,"
"believe," "will," "will likely," "should," "could," "would," "may"
or the negative of such terms and other comparable terminology. All
such forward-looking statements are based on current expectations
and are subject to risks and uncertainties. Should any of these
risks or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024